85 results about "Polyribonucleotides" patented technology

The present disclosure provides a method for analyzing a polyribonucleotide, wherein the polyribonucleotide is an mRNA molecule with a poly(A) tail, said method comprising: (a) obtaining a labeled polyribonucleotide by GI tailing; followed by (b) providing a second molecule comprising a first primer recognition sequence followed by a sequence of C nucleotide residues linked to a sequence of T nucleotide residues; followed by (c) obtaining a complex of said labeled polyribonucleotide and said second molecule; followed by (d) obtaining an extended second molecule by (d1) extending the 3′ end of the second molecule by synthesizing a sequence that is complementary to the labeled polyribonucleotide; followed by (d2) extending the 3′ end of the second molecule by adding at least 1 to 5 C nucleotide residues, followed by a second primer recognition sequence; said method providing information on entire polyribonucleotides, in particular mRNA isoforms and their respective poly(A) tails.

The present disclosure relates, generally, to methods for producing, purifying, and using circular RNA from a prokaryotic system.

The present disclosure relates, generally, to compositions and methods for producing, purifying, and using circular RNA.

This disclosure provides compositions, pharmaceutical preparations, and methods relating to circular polyribonucleotides encoding the expression of Varicella-Zoster Virus immunogens.

The disclosure provides compositions, pharmaceutical preparations, and uses of circular polyribonucleotides complexed with one or more targeting moieties. The disclosure further discloses methods of using targeting moieties complexed with a circular polyribonucleotide to achieve functional delivery of a polypeptide to a cell.

The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivering anti-HIV antibody agents and related techniques (e.g., components thereof and / or methods related thereto). In addition to this, the present disclosure also provides polyribonucleotides encoding an immunoglobulin chain of an anti-HIV antibody agent.

The present disclosure describes methods, kits, and systems for digesting polyribonucleotides. The methods involve selectively forming an oligonucleotide (e.g., DNA: RNA or RNA: RNA) duplex with a single-stranded target RNA, and then selectively cleaving the target RNA into smaller fragments using a sequence-specific nuclease that acts only on the RNA within the duplex. Additional sequence-specific ribonucleases can be used to provide additional cleavage of the target RNA at a predetermined site. By forming double strands to increase the availability of nuclease enzymes that can be used to cleave the single-stranded target RNA and to selectively control the location at which the target RNA is cleaved, the target RNA can be digested into fragments within a controllable size range that are optimal for polynucleotide analysis, such as by liquid chromatography and mass spectrometry.

Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising 2′-O-acetylated ribose, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present disclosure and methods of making and using the same.

The present disclosure provides compositions (e.g., pharmaceutical compositions) and related techniques (e.g., components thereof and / or methods related thereto) for delivery of malaria protein antigens. The present disclosure provides, among other things, polyribonucleotides encoding malaria protein antigens.

Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising 2′-O-acetylated ribose, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present disclosure and methods of making and using the same.

The present disclosure provides a polyribonucleotide encoding a polypeptide comprising a viral antigen from herpes simplex virus-2 (HSV-2); for example, the viral antigens comprise an extracellular domain of HSV-2 glycoprotein B. The polyribonucleotides can be formulated as RNA compositions that can be used to induce an anti-HSV immune response in a subject.

The present disclosure provides circular polyribonucleotides including a sequence including: a circularization element; a first spacer; an internal ribosome entry site (IRES) sequence; a sequence encoding a polypeptide; and a second spacer, where the sequence encoding the polypeptide has been codon-optimized to reduce the number of uracil ribonucleotides and / or reduce or remove TLR7- and TLR8-recognition motifs, and kits and compositions thereof. The present disclosure also provides methods of treating subjects in need thereof with the circular polyribonucleotides and compositions described herein.

To provide pharmaceutical compositions and preparations of modified circular polyribonucleotides, and to provide uses thereof.SOLUTION: The present disclosure provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier or excipient and a circular polyribonucleotide comprising a first portion of contiguous unmodified nucleotides. In some embodiments, the circular polyribonucleotide comprises at least one modified polyribonucleotide and a first portion of contiguous unmodified nucleotides. In some embodiments, the modified circular polyribonucleotide is delivered to a subject.SELECTED DRAWING: None

The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of anti-HIV antibody agents and related technologies (e.g., components thereof and / or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding an immunoglobulin chain of an anti-HIV antibody agent.

The disclosure provides compositions, pharmaceutical preparations, and uses of circular polyribonucleotides complexed with one or more targeting moieties. The disclosure further discloses methods of using targeting moieties complexed with a circular polyribonucleotide to achieve functional delivery of a polypeptide to a cell.

This disclosure relates to lipid compounds and lipid nanoparticles (LNPs) prepared therefrom that are particularly effective in delivery of circular polyribonucleotides. Methods of use of the lipid compounds and LNPs, e.g., for circular RNA delivery, are also provided.

The present disclosure provides circular polyribonucleotides including a sequence encoding a polypeptide including (i) a glucagon-like peptide-1 (GLP-1) polypeptide or analog thereof, (ii) a half-life extension moiety, and optionally (iii) a secretion signal sequence, and kits and compositions thereof. The present disclosure also provides methods of treating GLP-1 related diseases with compositions described herein.

The present disclosure provides pharmaceutical compositions for delivery of orthopoxvirus antigens (e.g., mpox, variola, borealpox, ectromelia, cowpox, volepox, modified vaccinia virus Ankara, or vaccinia) and related technologies (e.g., components thereof and / or methods relating thereto). For example, the present disclosure provides polyribonucleotides encoding one or more mpox antigens, fragments, or fusions thereof.

The present disclosure provides compositions (e.g., pharmaceutical compositions) and related technology (e.g., components thereof and / or methods related thereto) for the delivery of malaria protein antigens. Among other things, the present disclosure provides polyribonucleotides encoding malaria protein antigens.

The present disclosure provides compositions (e.g., pharmaceutical compositions) and related technology (e.g., components thereof and / or methods related thereto) for delivery of anti-HIV antibody agents. The present disclosure provides, among other things, polyribonucleotides encoding immunoglobulin chains of anti-HIV antibody agents. The present disclosure recognizes that HIV mutates rapidly. The highly mutating nature of HIV virions allows them to escape host immune and / or therapeutic pressures.